Annual report
3034.TEDINET S100R83W
Period2022-04-01 → 2023-03-31
Filed2023-06-29
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Amended by S100RBR1 (2023-07-04).
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥170.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥166.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥161.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥165.4bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥144.8bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥9.5bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥9.9bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥10.1bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥10.1bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥7.4bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥8.0bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.2bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥9.6bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥9.7bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥5.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.4bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥4.1bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.9bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥5.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥5.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥101.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥96.0bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥100.6bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥102.9bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥94.2bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥53.0bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥52.1bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥48.9bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥43.9bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥41.8bn | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥41.0bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥39.0bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥18.8bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥16.7bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥18.6bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥16.5bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥19.5bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥15.8bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥20.2bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥11.7bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥10.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥12.9bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥4.5bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥5.8bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥7.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥8.7bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥8.3bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥2.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥10.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥6.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥225m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥2.9bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥152.96 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥149.51 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥89.55 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥107.23 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥101.73 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥1,314.69 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,189.7 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,124.31 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,074.57 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,006.55 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 47.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.7% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.9% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.4% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.1% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 12.2% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.9% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.2% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.3% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.5% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 5,746 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 5,620 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 5,517 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 5,366 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 5,070 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥8.3bn | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥7.0bn | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥7.1bn | 2020-04-01 → 2021-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥4.2bn | 2019-04-01 → 2020-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥50.2bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥6.5bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥5.4bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥6.6bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥5.5bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥5.5bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.1bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.1bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥6.6bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥5.5bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥6.6bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥5.4bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥5.5bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥3.1bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.2bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥77.5bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥67.4bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥63.9bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥57.8bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥44.0bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥30.8bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥26.5bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥46.7bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥40.8bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥36.2bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥33.3bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥32.6bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥5.5bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.2bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥178 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥146.91 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥147.45 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥80.76 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥30.6 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥32 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,258.81 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,108.12 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥987.71 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥884.2 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥846.23 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 60.3% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.6% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.6% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.6% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.0% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 15.0% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.0% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.9% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.3% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.5% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 38,902,785 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 38,902,785 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 38,902,785 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 38,902,785 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 38,902,785 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 66 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 56 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 49 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 50 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 35 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 56
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥170m |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥29m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥404m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥404m |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | −¥1.2bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥3.5bn |
| Health Insurance Pharmacyreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥8.5bn |
| Health Insurance Pharmacyreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥1.4bn |
| Health Insurance Pharmacyreportable segment | employees | at 2023-03-31 | 4836 pure |
| Health Insurance Pharmacyreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥155.4bn |
| Health Insurance Pharmacyreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥155.4bn |
| Health Insurance Pharmacyreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥76m |
| Health Insurance Pharmacyreportable segment | segment assets | at 2023-03-31 | ¥92.1bn |
| Health Insurance Pharmacyreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥11.5bn |
| Medical Related Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥205m |
| Medical Related Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥118m |
| Medical Related Businessreportable segment | employees | at 2023-03-31 | 803 pure |
| Medical Related Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥15.0bn |
| Medical Related Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥14.7bn |
| Medical Related Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥328m |
| Medical Related Businessreportable segment | segment assets | at 2023-03-31 | ¥11.0bn |
| Medical Related Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥1.5bn |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥8.7bn |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥1.5bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥170.4bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥170.0bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥404m |
| —segment total | segment assets | at 2023-03-31 | ¥103.1bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥13.0bn |
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥80m |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥7m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥437m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥437m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | −¥2.5bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥3.2bn |
| Health Insurance Pharmacyreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥3.1bn |
| Health Insurance Pharmacyreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥1.3bn |
| Health Insurance Pharmacyreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥153.2bn |
| Health Insurance Pharmacyreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥153.1bn |
| Health Insurance Pharmacyreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥59m |
| Health Insurance Pharmacyreportable segment | segment assets | at 2022-03-31 | ¥87.9bn |
| Health Insurance Pharmacyreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥11.9bn |
| Medical Related Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥223m |
| Medical Related Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥102m |
| Medical Related Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥13.5bn |
| Medical Related Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥13.1bn |
| Medical Related Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥377m |
| Medical Related Businessreportable segment | segment assets | at 2022-03-31 | ¥10.6bn |
| Medical Related Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥1.2bn |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥3.3bn |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥1.4bn |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥166.6bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥166.2bn |
| —segment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥437m |
| —segment total | segment assets | at 2022-03-31 | ¥98.5bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥13.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,442
| Item | Context | Value | Unit |
|---|---|---|---|
| Total changes of items during the period | CurrentYearDuration_ValuationDifferenceOnAvailableForSaleSecuritiesMember | -0 | JPY |
| Total changes of items during the period | CurrentYearDuration_ValuationAndTranslationAdjustmentsMember | -0 | JPY |
| Total changes of items during the period | CurrentYearDuration_NonControllingInterestsMember | 1000000 | JPY |
| Total changes of items during the period | CurrentYearDuration | 4974000000 | JPY |
| Net assets | CurrentYearInstant_CapitalStockMember | 5786000000 | JPY |
| Net assets | CurrentYearInstant_CapitalSurplusMember | 11276000000 | JPY |
| Net assets | CurrentYearInstant_RetainedEarningsMember | 34355000000 | JPY |
| Net assets | CurrentYearInstant_TreasuryStockMember | -2596000000 | JPY |
| Net assets | CurrentYearInstant_ShareholdersEquityMember | 48823000000 | JPY |
| Net assets | CurrentYearInstant_ValuationDifferenceOnAvailableForSaleSecuritiesMember | -14000000 | JPY |
| Net assets | CurrentYearInstant_ValuationAndTranslationAdjustmentsMember | -14000000 | JPY |
| Net assets | CurrentYearInstant_NonControllingInterestsMember | 47000000 | JPY |
| Net assets | CurrentYearInstant | 48856000000 | JPY |
| Income before income taxes | Prior1YearDuration | 9687000000 | JPY |
| Income before income taxes | CurrentYearDuration | 9584000000 | JPY |
| Depreciation and amortization ope cf | Prior1YearDuration | 1565000000 | JPY |
| Depreciation and amortization ope cf | CurrentYearDuration | 1680000000 | JPY |
| Amortization of goodwill ope cf | Prior1YearDuration | 3168000000 | JPY |
| Amortization of goodwill ope cf | CurrentYearDuration | 3204000000 | JPY |
| Increase decrease in provision for directors retirement benefits ope cf | Prior1YearDuration | -200000000 | JPY |
| Increase decrease in provision for directors retirement benefits ope cf | CurrentYearDuration | -0 | JPY |
| Increase decrease in net defined benefit liability ope cf | Prior1YearDuration | -16000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | CurrentYearDuration | 36000000 | JPY |
| Increase decrease in provision for bonuses ope cf | Prior1YearDuration | 37000000 | JPY |
| Increase decrease in provision for bonuses ope cf | CurrentYearDuration | -47000000 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | Prior1YearDuration | -2000000 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | CurrentYearDuration | 9000000 | JPY |
| Loss gain on sales and retirement of noncurrent assets ope cf | Prior1YearDuration | 49000000 | JPY |
| Loss gain on sales and retirement of noncurrent assets ope cf | CurrentYearDuration | 45000000 | JPY |
| Impairment loss ope cf | Prior1YearDuration | 374000000 | JPY |
| Impairment loss ope cf | CurrentYearDuration | 460000000 | JPY |
| Loss on valuation of shares of subsidiaries ope cf | Prior1YearDuration | 49000000 | JPY |
| Loss on valuation of shares of subsidiaries ope cf | CurrentYearDuration | － | JPY |
| Gain on reversal of provision for withdraw loss from employees pension fund ope cf | Prior1YearDuration | -71000000 | JPY |
| Gain on reversal of provision for withdraw loss from employees pension fund ope cf | CurrentYearDuration | － | JPY |
| Gain on sales of investment securities ope cf | Prior1YearDuration | -0 | JPY |
| Gain on sales of investment securities ope cf | CurrentYearDuration | － | JPY |
| Surrender value of insurance ope cf | Prior1YearDuration | -5000000 | JPY |
| Surrender value of insurance ope cf | CurrentYearDuration | -229000000 | JPY |
| Interest and dividends income ope cf | Prior1YearDuration | -5000000 | JPY |
| Interest and dividends income ope cf | CurrentYearDuration | -6000000 | JPY |
| Interest expenses ope cf | Prior1YearDuration | 101000000 | JPY |
| Interest expenses ope cf | CurrentYearDuration | 89000000 | JPY |
| Decrease increase in inventories ope cf | Prior1YearDuration | -651000000 | JPY |
| Decrease increase in inventories ope cf | CurrentYearDuration | 703000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1YearDuration | 1042000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | CurrentYearDuration | 1135000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1YearDuration | -1583000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | CurrentYearDuration | 625000000 | JPY |
| Other net ope cf | Prior1YearDuration | -42000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |